MedTrace Logo

Study of Safety and Efficacy of the Drug Cycloferone in Patients with Acute Respiratory Viral Infection

NCT06286254 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 742

Last updated 2024-12-16

No results posted yet for this study

Summary

The study will collect the information on clinical effects and safety of the basic therapy of acute respiratory viral infection (ARVI) + Cycloferone® and basic therapy of ARVI1 + Arbidol® in real-life clinical settings.

Conditions

  • Acute Respiratory Viral Infection

Interventions

DRUG

Cycloferone

Cycloferone® is administered according to the instruction for medical use: 600 mg (4 tablets) once daily on day 1, 2, 4, 6 and 8.

Sponsors & Collaborators

  • POLYSAN Scientific & Technological Pharmaceutical Company

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-20
Primary Completion
2024-04-20
Completion
2024-09-30

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06286254 on ClinicalTrials.gov